As of 12:00pm ET
| -0.065 / -2.31%|
The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +300.73% increase from the last price of 2.75.
The current consensus among 6 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.